A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications

References

• National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria: The National Department of Health; 2015. p. 119.
   Google Scholar
• Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011;15(8):1803–1808.
   PubMed Web of Science ®Google Scholar
• Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009;11(2):103–109.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med. 2009;151(3):149–156.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Evans S, Yang Y, et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10(6):343–355.
   PubMed Web of Science ®Google Scholar
• Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. J Acq Immun Def Synd. 2005;38(5):560–565.
   PubMed Web of Science ®Google Scholar
• Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6(4):187–196.
   PubMed Web of Science ®Google Scholar
• Adco-Efavirenz [package insert]. Midrand (Gauteng): Adcock Ingram; 2007.
   Google Scholar
• Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acq Immun Def Synd. 2001;27(4):336–343.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143(10):714–721.
   PubMed Web of Science ®Google Scholar
• Gutierrez F, Navarro A, Padillo S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41(11):1648–1653.
   PubMed Web of Science ®Google Scholar
• Hoffman CJ, Fielding KL, Charalambous S, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS. 2008;2(1):670–674.
   Google Scholar
• Leutscher PDC, Stecher C, Storgaard M, et al. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis. 2013;45(8):645–651.
   PubMed Web of Science ®Google Scholar
• Lochet P, Peyrière H, Lotthé A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4(1):62–66.
   PubMedGoogle Scholar
• Nelson M, Stellbrink H, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 2011;25(3):335–340.
   PubMed Web of Science ®Google Scholar
• Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006;7(8):544–548.
   PubMed Web of Science ®Google Scholar
• Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDs. 2006;20(8):542–548.
   PubMed Web of Science ®Google Scholar
• Naidoo P, Chetty VV, Chetty M. Impact of CYP polymorphisms, ethnicity, and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol. 2014;70(4):379–389.
   PubMed Web of Science ®Google Scholar
• Napoli AA, Wood JJ, Coumbis JJ, et al. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc. 2014;17:19214.
   PubMed Web of Science ®Google Scholar
• Smith C, Ryom L, d’Arminio Monforte A, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc. 2014;17(4suppl3):19512.
   PubMedGoogle Scholar
• Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161(1):1–10.
   PubMed Web of Science ®Google Scholar
• Von Giesen HJ, Köller H, De Nocker D, et al. Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials. 2003;4(6):382–390.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on antiretroviral guidelines for adult and adolescents. Department of Health and Human Services; 2015.
   Google Scholar
• British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. British HIV Association; 2015.
   Google Scholar
• Unicef. Eastern and Southern Africa HIV and AIDS. [ cited 2015 Dec 27]. Available from: http://www.unicef.org/esaro/5482_HIV_AIDS.html.
   Google Scholar
• Botswana national HIV and AIDS treatment guidelines. Gaborone: Ministry of Health; 2012. p. 197. Available from: http://www.med.upenn.edu/botswana/user_documents/BotsNatHIV-AIDSTreatGuide WEB22-05-2012.pdf
   Google Scholar
• National guidelines on the use of antiretroviral therapy for HIV prevention and treatment. Lesotho: Ministry of Health; 2014. p. 140. Available from: http://www.emtct-iatt.org/wp-content/uploads/2015/02/National-ART-Guidelines_Final_16-June-20142.pdf
   Google Scholar
• Clinical management of HIV in children and adults. Malawi: Ministry of Health; 2014. p. 105. Available from: http://www.emtct-iatt.org/wp-content/uploads/2015/09/Malawi-HIV-Guidelines-2014.pdf
   Google Scholar
• National guidelines for antiretroviral therapy. Republic of Namibia Ministry of Health and Social Services; 2010. p. 90. Available from: http://www.who.int/hiv/pub/guidelines/namibia_art.pdf
   Google Scholar
• National comprehensive HIV package of care for adults and adolescents in Swaziland. Kingdom of Swaziland: Ministry of Health; 2010. p. 174. Available from: http://www.who.int/hiv/pub/guidelines/swaziland_art.pdf
   Google Scholar
• National comprehensive HIV package of care for adults and adolescents in Swaziland. Kingdom of Swaziland: Ministry of Health; 2015. 165p.
   Google Scholar
• Antiretroviral therapy for HIV infection in adults and adolescents recommendations for a public health approach. World Health Organisation: Austria; 2010. 156p.
   Google Scholar
• The World Bank Data: Country and Lending Groups. 2015. Available form: http://data.worldbank.org/about/country-and-lending-groups
   Google Scholar
• Guidelines for antiretroviral therapy for the prevention and treatment of HIV in Zimbabwe. Harare: The National Medicine and Therapeutics Policy Advisory Committee and The AIDS and TB Directorate, Ministry of Health and Child Care; 2013. p. 88. Available from: http://www.nac.org.zw/sites/default/files/2013%20Zimbabwe%20ARV%20Guidelines%20%20Main%20Document%20(1).pdf
   Google Scholar
• Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 2001;15(1):71–75.
   PubMed Web of Science ®Google Scholar
• Ngaimisi E, Habtewold A, Minzi O, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan African populations. PLoS ONE. 2013;8(7):e67946.
   PubMed Web of Science ®Google Scholar
• Massele A, Burger J, Katende-Kyenda NL, et al. Outcome of the first medicines utilization research in Africa group meeting to promote sustainable and rational medicine use in Africa. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):885–888.
   Web of Science ®Google Scholar
• AVERT. HIV and AIDS in sub-Saharan Africa regional overview. [ cited 2015 Aug 20]. Available from: http://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/overview.
   Google Scholar
• Leclerc-Madlala S. Age-disparate and intergenerational sex in southern Africa: the dynamics of hypervulnerability. AIDS (London, England). 2008;22(Suppl 4):S17–25.
   PubMed Web of Science ®Google Scholar